Respiratory syncytial virus outbreak defined by rapid screening in a neonatal intensive care unit

Palivizumab is currently licensed for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in infants and children with chronic lung disease, with a history of preterm birth, or with haemodynamically significant congenital heart disease, but its routine use during outb...

Descripción completa

Detalles Bibliográficos
Autores principales: Dizdar, E.A., Aydemir, C., Erdeve, O., Sari, F.N., Oguz, S., Uras, N., Dilmen, U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Hospital Infection Society. Published by Elsevier Ltd. 2010
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132464/
https://www.ncbi.nlm.nih.gov/pubmed/20299133
http://dx.doi.org/10.1016/j.jhin.2010.01.013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132464/
https://www.ncbi.nlm.nih.gov/pubmed/20299133
http://dx.doi.org/10.1016/j.jhin.2010.01.013

Ejemplares similares